ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
Dow Jones
42.392,27
-0,36%
Euro vs US Dollar
1,02672
0,00%
Bitcoin
96.887,52
-0,01%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Werewolf Therapeutics Inc (HOWL)

  7. Werewolf Therapeutics Inc (HOWL) News

HOWL

Werewolf Therapeutics (HOWL)

Werewolf Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:HOWL
DatumZeitQuelleÜberschriftSymbolFirma
20/11/202414h00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202415h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202415h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202415h02GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/11/202415h00GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
31/10/202413h00GlobeNewswire Inc.Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory DiseasesNASDAQ:HOWLWerewolf Therapeutics Inc
04/10/202415h00GlobeNewswire Inc.Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202413h21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202413h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202413h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
08/08/202413h05GlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
25/06/202413h00GlobeNewswire Inc.Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomaNASDAQ:HOWLWerewolf Therapeutics Inc
03/06/202413h56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202415h00GlobeNewswire Inc.Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid TumorsNASDAQ:HOWLWerewolf Therapeutics Inc
30/05/202414h00GlobeNewswire Inc.Werewolf Therapeutics to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
28/05/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202401h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202401h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202401h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202401h44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
23/05/202423h00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/05/202413h00GlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
24/04/202416h05GlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
23/04/202414h00GlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
05/04/202422h30GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/04/202422h30GlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413h22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:HOWL

Kürzlich von Ihnen besucht

AMEX
DLA
Delta Apparel
NASDAQ
CDSSX
Ci Global Equity Pool Se...
DOWI
DJUSAV
DJ US Media Agencies
UNSW
STARLETH
StarLink
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten